Shareholders were having a pleasant month until Ophthotech's frenemy Regeneron Pharmaceuticals (NASDAQ:REGN) reported clinical data that gave investors pause.
Regeneron released data from its phase 2 CAPELLA study in late September. This trial was testing its experimental compound rinucumab -- an anti-platelet-derived growth factor receptor beta (anti-PDGFR-beta) antibody -- in combination with its blockbuster eye disease drug Eylea as a hopeful treatment for neovascular age-related macular degeneration (wet AMD).
The data showed that the combination therapy failed to outperform Eylea as a monotherapy. In fact, patients who received Eylea and rinucumab only demonstrated a 5.8 letter improvement on the BCVA test, which was worse than the 7.5 letter improvement observed in the monotherapy group.
While Ophthotech's lead compound Fovista was not used in this study, traders now have a renewed worry that anti-PDGF drugs like Fovista might not improve upon current standards of care. In response, they sold off the company's shares.
While it's tempting to look at this data and conclude that Fovista is dead in the water, I think it's still too early to draw any real conclusions. After all, Phase 2b studies showed that adding Fovista to Novartis' Lucentis lead to a 62% improvement in eyesight when compared to using Lucentis as a monotherapy. If the company can repeat those results when they release data from a Phase 3 study in the upcoming months, then these renewed fears will likely to put to rest. In turn, I'd expect the company's shares to soar.
Of course, if Ophthotech's updated data suggests that anti-PDGF drugs do not lead to a clinical benefit, then look out below. That makes Ophtotech a high-risk, high-reward stock that should only be owned by shareholders who are willing to face a significant binary event.